Jeff Bernstein Joins Parexel’s Board, Bringing Extensive Healthcare Investment And Leadership Experience

Parexel, a leading global clinical research organization (CRO) offering Phase I to IV clinical development services, has announced the appointment of Jeff Bernstein to its Board of Directors, effective March 5, 2025. Bernstein, a Partner at Goldman Sachs Asset Management and Co-Head of Goldman Sachs Healthcare Private Equity Investing, replaces Michael Bruun as part of a planned board rotation.

Mr. Bernstein also expressed, “I’m extremely pleased to join Parexel’s Board. I look forward to supporting the company as it differentiates and innovates to advance its position as a leading global CRO and accelerate the delivery of life-enhancing new therapies to patients worldwide.”

Bernstein brings extensive experience in healthcare investments, finance, and board leadership. Having joined Goldman Sachs in 2008, he was promoted to Managing Director in 2019 and became a Partner in 2024. His expertise spans multiple healthcare companies, where he has played a critical role in financial strategy and growth initiatives. 

Sheri McCoy, Chairperson of the Board, commented, “Jeff’s extensive background in healthcare will be a great asset to the Board as we prepare for the next phase of Parexel’s growth. We look forward to leveraging his insights as we work to advance our strategic roadmap and deliver on our growth objectives.”

Currently, Bernstein serves on the boards of Advanced Recovery Systems, AvaSure, MyEyeDr., and MDVIP. His past board roles include Brighton Health Plan Solutions, Privia Health Group, and Upstream Rehabilitation. He holds a Bachelor of Arts in Economics and a Finance certificate from Princeton University. His appointment is expected to strengthen Parexel’s strategic direction and financial leadership.

“Michael Bruun has been a tremendous asset to our Board over the past two years, and we’re incredibly grateful for his engagement, guidance and leadership. We thank Michael for his service and wish him the very best in his future endeavours,” said Peyton Howell, Chief Executive Officer.

She continued, “We’re delighted to welcome Jeff Bernstein to the Parexel Board. His deep knowledge across the global financial and healthcare landscape will be invaluable as we work to create even greater value for our stakeholders in 2025 by leveraging unique insights, driving best-in-class delivery and building trust to achieve market-leading growth.”